Log in

NASDAQ:LIVNLivaNova Stock Price, Forecast & News

$48.53
-0.05 (-0.10 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$47.54
Now: $48.53
$48.61
50-Day Range
$45.75
MA: $50.90
$57.81
52-Week Range
$33.40
Now: $48.53
$87.45
Volume233,979 shs
Average Volume578,708 shs
Market Capitalization$2.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.81
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, treatment-resistant depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company was founded in 1987 and is headquartered in London, the United Kingdom.
Read More
LivaNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.41 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LIVN
CUSIPN/A
Phone44-0-20-3325-0660

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.08 billion
Cash Flow$5.88 per share
Book Value$28.59 per share

Profitability

Net Income$-155,180,000.00

Miscellaneous

Employees4,000
Market Cap$2.36 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$48.53
-0.05 (-0.10 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LIVN News and Ratings via Email

Sign-up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











LivaNova (NASDAQ:LIVN) Frequently Asked Questions

How has LivaNova's stock been impacted by Coronavirus (COVID-19)?

LivaNova's stock was trading at $62.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, LIVN stock has decreased by 22.5% and is now trading at $48.53.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of LivaNova?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LivaNova in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for LivaNova
.

When is LivaNova's next earnings date?

LivaNova is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for LivaNova
.

How were LivaNova's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday, July, 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.15. The company had revenue of $182.20 million for the quarter, compared to analyst estimates of $169.74 million. LivaNova had a negative net margin of 16.47% and a positive return on equity of 7.00%. The business's revenue was down 34.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.70 EPS.
View LivaNova's earnings history
.

What guidance has LivaNova issued on next quarter's earnings?

LivaNova updated its FY20 earnings guidance on Wednesday, July, 29th. The company provided earnings per share guidance of $1.15-1.35 for the period, compared to the Thomson Reuters consensus estimate of $1.47. The company issued revenue guidance of decline 7-17% yr/yr to $900 million to $1.01 billion, compared to the consensus revenue estimate of $937.94 million.

What price target have analysts set for LIVN?

7 brokerages have issued 1-year price targets for LivaNova's shares. Their forecasts range from $40.00 to $114.00. On average, they expect LivaNova's share price to reach $68.43 in the next year. This suggests a possible upside of 41.0% from the stock's current price.
View analysts' price targets for LivaNova
.

Has LivaNova been receiving favorable news coverage?

News stories about LIVN stock have trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. LivaNova earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.
View the latest news about LivaNova
.

Are investors shorting LivaNova?

LivaNova saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 3,160,000 shares, an increase of 61.2% from the June 15th total of 1,960,000 shares. Based on an average trading volume of 637,000 shares, the short-interest ratio is presently 5.0 days.
View LivaNova's Short Interest
.

Who are some of LivaNova's key competitors?

What other stocks do shareholders of LivaNova own?

Who are LivaNova's key executives?

LivaNova's management team includes the following people:
  • Mr. Damien McDonald, CEO & Director (Age 54)
  • Mr. Thad Huston, Chief Financial Officer (Age 49)
  • Mr. Douglas J. Manko, Chief Accounting Officer (Age 45)
  • Ms. Keyna Pidcock Skeffington, Gen. Counsel & Sr. VP (Age 56)
  • Mr. David S. Wise, Sr. Advisor (Age 64)

What is LivaNova's stock symbol?

LivaNova trades on the NASDAQ under the ticker symbol "LIVN."

Who are LivaNova's major shareholders?

LivaNova's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.46%), Paradice Investment Management LLC (1.72%), Point72 Asset Management L.P. (1.28%), Federated Hermes Inc. (1.28%), Bank of America Corp DE (1.09%) and Bank of New York Mellon Corp (1.07%). Company insiders that own LivaNova stock include Alfred J Novak, Alistair Simpson, Damien Mcdonald, Daniel Jeffrey Moore, David S Wise, Douglas John Manko, Hugh M Morrison, Thad Allen Huston and William A Kozy.
View institutional ownership trends for LivaNova
.

Which major investors are selling LivaNova stock?

LIVN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Goldman Sachs Group Inc., FIL Ltd, Cubist Systematic Strategies LLC, Prudential Financial Inc., UBS Group AG, Hosking Partners LLP, and Strs Ohio. Company insiders that have sold LivaNova company stock in the last year include Damien Mcdonald, and Daniel Jeffrey Moore.
View insider buying and selling activity for LivaNova
.

Which major investors are buying LivaNova stock?

LIVN stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Marshall Wace LLP, Hudson Bay Capital Management LP, Diamond Hill Capital Management Inc., Brandes Investment Partners LP, KEYWISE CAPITAL MANAGEMENT HK Ltd, Bank of America Corp DE, and Balyasny Asset Management LLC. Company insiders that have bought LivaNova stock in the last two years include Alfred J Novak, and William A Kozy.
View insider buying and selling activity for LivaNova
.

How do I buy shares of LivaNova?

Shares of LIVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is LivaNova's stock price today?

One share of LIVN stock can currently be purchased for approximately $48.53.

How big of a company is LivaNova?

LivaNova has a market capitalization of $2.36 billion and generates $1.08 billion in revenue each year. The company earns $-155,180,000.00 in net income (profit) each year or $3.08 on an earnings per share basis. LivaNova employs 4,000 workers across the globe.

What is LivaNova's official website?

The official website for LivaNova is www.livanova.com.

How can I contact LivaNova?

LivaNova's mailing address is 20 EASTBOURNE TERRACE, LONDON X0, W2 6LG. The company can be reached via phone at 44-0-20-3325-0660 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.